News Sentiment

ABBV sentiment intelligence

AbbVie Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors Options RSS feed
Weighted score 55 Balanced news tone 44 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Drug Manufacturers - General Read-through group
Latest close 248.08 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 44

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-5.0% over one week, +8.9% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Analysts Are Bullish on Top Healthcare Stocks: Fractyl Health, Inc. (GUTS), AbbVie (ABBV)

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction -5.0% Price reacting lower
Trend fit Trend active 8.9% over four weeks
Fair value 36.9% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 30
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 44
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
TradingView 5
simplywall.st 4
The Globe and Mail 3
Pharmaceutical Executive 3
StockStory 2
Ad Hoc News 1
Quiver Quantitative 1

Event Lens

What the news is about

Classified themes
Market update 26
Analyst action 4
Deals and strategy 4
Earnings 3
Capital return 2
Regulatory and legal 2
Guidance 2
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 44
The Globe and Mail Direct company coverage

Analysts Are Bullish on Top Healthcare Stocks: Fractyl Health, Inc. (GUTS), AbbVie (ABBV)

Healthcare sector analysts have issued bullish sentiments on Fractyl Health, Inc. (GUTS) and AbbVie (ABBV). H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating for Fractyl Health with an $8.00 price target, while William Blair analyst Matt Phipps maintained a Buy rat

Tone
Positive 87/100
Event
Analyst action
Published
16 Jul 2026 19:00
Source
The Globe and Mail
Ad Hoc News Direct company coverage

AbbVie stock trades steadily as investors weigh Humira erosion and pipeline progress

AbbVie Inc. is navigating a transitional period marked by the decline of its flagship drug Humira due to biosimilar competition, balanced by the growth of its newer immunology and neuroscience treatments. Investors are focusing on the pace at which these new therapies can offset

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 17:46
Source
Ad Hoc News
TradingView Direct company coverage

Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter?

AbbVie (ABBV) is set to report its second-quarter 2026 results, with investor attention on its neuroscience portfolio following a 26% revenue increase in Q1. The Zacks Consensus Estimate predicts 15% year-over-year growth for neuroscience revenues, driven by drugs like Botox Ther

Tone
Positive 63/100
Event
Earnings
Published
16 Jul 2026 17:07
Source
TradingView
Quiver Quantitative Direct company coverage

Why AbbVie (ABBV) Stock Is Up Today

AbbVie (ABBV) stock rose 3.3% today, driven by positive Wall Street sentiment and anticipation of its second-quarter earnings report. Analyst price target increases and new regulatory submissions for drugs like RINVOQ and SKYRIZI indicate strong pipeline momentum, despite ongoing

Tone
Positive 71/100
Event
Analyst action
Published
16 Jul 2026 15:36
Source
Quiver Quantitative
TradingKey Direct company coverage

AbbVie Inc Stock (ABBV) Moved Up by 3.32% on Jul 16: What Signal Does It Send?

AbbVie Inc.'s stock (ABBV) rose by 3.32% due to positive clinical trial outcomes for Skyrizi and Rinvoq, reinforcing its post-Humira growth strategy. Institutional investors are favoring healthcare stocks like AbbVie for its dividend profile and resilient cash flow, amidst a broa

Tone
Positive 75/100
Event
Capital return
Published
16 Jul 2026 15:15
Source
TradingKey
Simply Wall Street Direct company coverage

Is AbbVie (ABBV) Fully Priced Despite Tepkinly Approval And Cash Flow?

AbbVie (ABBV) stock has achieved a 150.7% return over five years, presenting a mixed valuation picture. While a Discounted Cash Flow (DCF) model suggests the stock is undervalued by 46.4% due to strong cash flow and recent Tepkinly approval, market-based multiples, specifically t

Tone
Neutral 50/100
Event
Regulatory and legal
Published
16 Jul 2026 10:24
Source
Simply Wall Street
TradingView Direct company coverage

Should You Buy, Sell or Hold ABBV Stock After Its 9% YTD Rise?

AbbVie (ABBV) stock has seen an 8.9% year-to-date rise, driven by investor confidence in its post-Humira growth strategy, particularly the success of Skyrizi and Rinvoq. Despite patent expiry challenges for Humira, the company is bolstering its pipeline through acquisitions like

Tone
Positive 66/100
Event
Deals and strategy
Published
15 Jul 2026 15:07
Source
TradingView
24/7 Wall St. Direct company coverage

AbbVie vs Baxter: One Golden Cross Is Real, One Is a Trap

This article analyzes a "golden cross" technical signal for both AbbVie (ABBV) and Baxter International (BAX), evaluating which stock is better suited for an income-focused retirement portfolio. It concludes that AbbVie is a clear winner due to its robust dividend, strong financi

Tone
Positive 75/100
Event
Capital return
Published
15 Jul 2026 11:46
Source
24/7 Wall St.
StockInvest.us Direct company coverage

Red day on Tuesday for AbbVie stock after losing 1.31%

AbbVie stock (ABBV) fell by 1.31% on July 14, 2026, marking its seventh consecutive daily decline and resulting in a 3.76% drop over the last 10 days. Despite negative short-term signals like a sell signal from a pivot top point, the stock has a general buy signal from its long-t

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 00:53
Source
StockInvest.us
MarketWatch Direct company coverage

AbbVie Inc. stock outperforms competitors despite losses on the day

AbbVie Inc. (ABBV) shares fell by 1.30% to $244.78 on Tuesday, marking its seventh consecutive day of losses, despite a generally favorable trading session for the broader stock market. The S&P 500 Index rose by 0.38% and the Dow Jones Industrial Average increased by 0.02%. The a

Tone
Negative 38/100
Event
Market update
Published
14 Jul 2026 16:31
Source
MarketWatch
Yahoo! Finance Canada Direct company coverage

Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic?

This article analyzes whether AbbVie (ABBV) is a wise investment, comparing its average brokerage recommendation (ABR) with the Zacks Rank. While Wall Street analysts have an optimistic outlook with an ABR of 1.61 (approximating Strong Buy), the Zacks Rank, a proprietary stock ra

Tone
Negative 36/100
Event
Guidance
Published
14 Jul 2026 13:37
Source
Yahoo! Finance Canada
Economies.com Direct company coverage

AbbVie price seeks a supportive bottom - Forecast today - 14-07-2026

AbbVie Inc. (ABBV) experienced a pullback due to bearish signals after reaching overbought territory, but is now seeking a higher low to rebuild positive momentum. Despite recent weakness, the stock remains above its 50-day Simple Moving Average, indicating a bullish outlook for

Tone
Positive 74/100
Event
Guidance
Published
14 Jul 2026 12:07
Source
Economies.com
The Globe and Mail Direct company coverage

Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb

Donald Trump's administration has implemented voluntary drug-pricing agreements with major pharmaceutical companies like Pfizer, AbbVie, and Bristol Myers Squibb, aligning drug prices with those in comparable developed countries. While these deals introduce some pricing pressure,

Tone
Positive 61/100
Event
Market update
Published
14 Jul 2026 09:19
Source
The Globe and Mail
ABC11 News Direct company coverage

AbbVie pharmaceutical project moves forward in Durham: 'Huge deal'

Durham County leaders are considering a $15 million incentive package for AbbVie, a major pharmaceutical company planning a $1.4 billion investment in a new Durham campus. This project highlights the region's growing pharmaceutical industry and the role of local institutions like

Tone
Positive 71/100
Event
Deals and strategy
Published
13 Jul 2026 21:51
Source
ABC11 News